| Trial ID: | L4055 |
| Source ID: | NCT00485758
|
| Associated Drug: |
Er Niacin/Laropiprant
|
| Title: |
Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00485758/results
|
| Conditions: |
Diabetes Mellitus Type 2
|
| Interventions: |
DRUG: ER niacin/laropiprant|DRUG: Comparator : placebo (unspecified)
|
| Outcome Measures: |
Primary: Percent Change at Week (Wk) 12 Compared to Baseline (Bl) in Low-density Lipoprotein Cholesterol in Patients With Type 2 Diabetes When Compared to Placebo, After 12 Weeks of treatment, to assess the reduction of low-density lipoprotein cholesterol in patients with Type 2 diabetes when compared to placebo, Baseline and 12 Weeks | Secondary: Percent Change at Week (Wk) 12 Compared to Baseline (Bl) in High Density Lipoprotein Cholesterol in Patients With Type 2 Diabetes When Compared to Placebo, After 12 weeks of treatment, to assess the increase of high-density lipoprotein cholesterol in patients with Type 2 diabetes when compared to placebo, Baseline and 12 Weeks|Percent Change at Week (Wk) 12 Compared to Baseline (Bl) in Triglycerides in Patients With Type 2 Diabetes When Compared to Placebo, after 12 weeks of treatment, to assess the reduction of triglycerides in patients with Type 2 diabetes when compared to placebo, Baseline and 12 Weeks
|
| Sponsor/Collaborators: |
Sponsor: Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
796
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2007-07
|
| Completion Date: |
2008-08
|
| Results First Posted: |
2009-09-11
|
| Last Update Posted: |
2015-10-12
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00485758
|
